BTG3 and systemic lupus erythematosus: A placebo-controlled trial was conducted in patients with seropositive SLE (anti-nuclear antibody [ANA], double-stranded DNA [dsDNA] and/or anti-Smith antibodies) and patients who had and active disease (SLEDAI ≥6, British Isles Lupus Assessment Group index [BILAG] A ≥1 and/or ≥2 BILAG B scores) despite standard therapy.